A phase i trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood

Neuro-Oncology

Volumn 15, Issue 6, 2013, Pages 783-787

  Cohen, Kenneth J ^a   Gibbs, Iris C ^b   Fisher, Paul G ^b   Hayashi, Robert J ^c   MacY, Margaret E ^d   Gore, Lia ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

arsenic trioxide; astrocytoma; chemoradiotherapy; pediatrics

Indexed keywords

ARSENIC TRIOXIDE;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; ASTROCYTOMA; CHEMORADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PONTINE GLIOMA; PRESCHOOL CHILD; SCHOOL CHILD; VOMITING;

ARSENIC TRIOXIDE; ASTROCYTOMA; CHEMORADIOTHERAPY; PEDIATRICS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; ASTROCYTOMA; BRAIN STEM NEOPLASMS; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; OXIDES; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84878269566     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not021     Document Type: Article

References (33)

1. Frazier JL, Lee J, Thomale UW, et al. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009; 3(4): 259-269.
2. Jansen MH, van Vuurden DG, Vandertop WP, et al. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012; 38(1): 27-35.
3. Gallagher RE. Arsenic - new life for an old potion. N Engl J Med. 1998; 339(19): 1389-1391.
4. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9): 3354-3360.
5. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998; 339(19): 1341-1348.
6. Sun H, Zhang S. Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2. Biochem Biophys Res Commun. 2011; 410(3): 692-697.
7. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 2001; 6(Suppl 2): 11-16.
8. Fox E, Razzouk BI, Widemann BC, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008; 111(2): 566-573.
9. Zhuang G, Zhou Y, Lu H, et al. Concentration of rare earth elements, As, and Th in human brain and brain tumors, determined by neutron activation analysis. Biol Trace Elem Res. 1996; 53(1-3): 45-49.
10. Vahter M, Norin H. Metabolism of 74As-labeled trivalent and pentavalent inorganic arsenic in mice. Environ Res. 1980; 21(2): 446-457.
11. Lew YS, Brown SL, Griffin RJ, et al. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res. 1999; 59(24): 6033-6037.
12. Kim JH, Lew YS, Kolozsvary A, et al. Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiat Res. 2003; 160(6): 662-666.
13. Kanzawa T, Zhang L, Xiao L, et al. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene. 2005; 24(6): 980-991.
14. Kanzawa T, Kondo Y, Ito H, et al. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003; 63(9): 2103-2108.
15. Zhao S, Tsuchida T, Kawakami K, et al. Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol. 2002; 21(1): 49-55.
16. Chiu HW, Ho SY, Guo HR, et al. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy. 2009; 5(4): 472-483.
17. Ning S, Knox SJ. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Int J Radiat Oncol Biol Phys. 2004; 60(1): 197-203.
18. Chiu HW, Ho YS, Wang YJ. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin. J Mol Med (Berl). 2011; 89(9): 927-941.
19. Haga N, Fujita N, Tsuruo T. Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells. Cancer Sci. 2005; 96(11): 825-833.
20. Izdebska M, Grzanka A, Szczepanski MA, et al. [Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment]. Postepy Hig Med Dosw (Online). 2008; 62: 463-467.
21. Liu SY, Wen CY, Lee YJ, et al. XPC silencing sensitizes glioma cells to arsenic trioxide via increased oxidative damage. Toxicol Sci. 2010; 116(1): 183-193.
22. Pucer A, Castino R, Mirkovic B, et al. Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. Biol Chem. 2010; 391(5): 519-531.
23. Wei Y, Liu D, Ge Y, et al. Down-regulation of beta1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis. Cancer Lett. 2008; 267(1): 96-105.
24. Xia ZB, Wu XJ, Qi TW, et al. [Study on inhibitory effect of arsenic trioxide on growth of rat C6 glioma cells]. Zhongguo Zhong Yao Za Zhi. 2008; 33(17): 2150-2153.
25. Ning S, Knox SJ. Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. Int J Radiat Oncol Biol Phys. 2006; 65(2): 493-498.
26. Tomuleasa C, Soritau O, Kacso G, et al. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. J BUON. 2010; 15(4): 758-762.
27. Zhen Y, Zhao S, Li Q, et al. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett. 2010; 292(1): 64-72.
28. Kim EH, Yoon MJ, Kim SU, et al. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res. 2008; 68(1): 266-275.
29. Song X, Chen Z, Wu C, et al. Abrogating HSP response augments cell death induced by As2O3 in glioma cell lines. Can J Neurol Sci. 2010; 37(4): 504-511.
30. Liu Y, Liang Y, Zheng T, et al. Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. J Neurooncol. 2011; 104(2): 449-458.
31. Kim J, Lee JJ, Gardner D, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010; 107(30): 13432-13437.
32. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011; 121(1): 148-160.
33. Raju GP. Arsenic: a potentially useful poison for Hedgehog-driven cancers. J Clin Invest. 2011; 121(1): 14-16.